Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform. Co.'s products and candidates for PH include: YUTREPIATM (treprostinil) Inhalation Powder to Treat PAH, which is an inhaled dry powder formulation of treprostinil; and Treprostinil Injection, a Generic Version of Remodulin®, which contains the same active ingredient, same strength, same dosage forms and same inactive ingredient amounts as Remodulin®. The LQDA YTD return is shown above.
The YTD Return on the LQDA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether LQDA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LQDA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|